A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs by Daskapan, Alper et al.
  
 University of Groningen
A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line
Tuberculosis Drugs
Daskapan, Alper; Idrus, Lusiana R; Postma, Maarten J; Wilffert, Bob; Kosterink, Jos G W;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Daskapan, A., Idrus, L. R., Postma, M. J., Wilffert, B., Kosterink, J. G. W., Stienstra, Y., ... Alffenaar, J-W.
C. (2018). A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line
Tuberculosis Drugs. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-018-0716-8
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the






A Systematic Review on the Effect of HIV Infection 
on the Pharmacokinetics of First‑Line Tuberculosis Drugs
Alper Daskapan1 · Lusiana R. Idrus2 · Maarten J. Postma2,3 · Bob Wilffert1,2 · Jos G. W. Kosterink1,2 · Ymkje Stienstra4 · 
Daniel J. Touw1,5 · Aase B. Andersen6 · Adrie Bekker7 · Paolo Denti8 · Agibothu K. Hemanth Kumar9 · 
Kidola Jeremiah10 · Awewura Kwara11 · Helen McIlleron8 · Graeme Meintjes12 · Joep J. van Oosterhout13,14 · 
Geetha Ramachandran9 · Neesha Rockwood12,15 · Robert J. Wilkinson12,15,16 · Tjip S. van der Werf4 · 
Jan‑Willem C. Alffenaar1
 
© The Author(s) 2018
Abstract
Introduction Contrasting findings have been published regarding the effect of human immunodeficiency virus (HIV) on 
tuberculosis (TB) drug pharmacokinetics (PK).
Objectives The aim of this systematic review was to investigate the effect of HIV infection on the PK of the first-line TB 
drugs (FLDs) rifampicin, isoniazid, pyrazinamide and ethambutol by assessing all published literature.
Methods Searches were performed in MEDLINE (through PubMed) and EMBASE to find original studies evaluating the 
effect of HIV infection on the PK of FLDs. The included studies were assessed for bias and clinical relevance. PK data were 
extracted to provide insight into the difference of FLD PK between HIV-positive and HIV-negative TB patients. This sys-
tematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
statement and its protocol was registered at PROSPERO (registration number CRD42017067250).
Results Overall, 27 studies were eligible for inclusion. The available studies provide a heterogeneous dataset from which 
consistent results could not be obtained. In both HIV-positive and HIV-negative TB groups, rifampicin (13 of 15) and etham-
butol (4 of 8) peak concentration (Cmax) often did not achieve the minimum reference values. More than half of the studies 
(11 of 20) that included both HIV-positive and HIV-negative TB groups showed statistically significantly altered FLD area 
under the concentration–time curve and/or Cmax for at least one FLD.
Conclusions HIV infection may be one of several factors that reduce FLD exposure. We could not make general recom-
mendations with respect to the role of dosing. There is a need for consistent and homogeneous studies to be conducted.
Key Points 
The available studies provide a heterogeneous dataset, 
and this study exposes the current knowledge gaps 
regarding the effect of human immunodeficiency virus 
(HIV) infection on the pharmacokinetics (PK) of first-
line tuberculosis drugs (FLDs).
There is a need for a consistent and homogeneous 
approach to studies, and for a uniform quality assessment 
tool for PK studies.
Taking clinical relevance into account, we postulate 
that HIV infection may increase the risk for low FLD 
exposure, with potential detrimental consequences for 
treatment outcomes.
 * Jan-Willem C. Alffenaar 
 j.w.c.alffenaar@umcg.nl
Extended author information available on the last page of the article
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1 Introduction
Tuberculosis (TB) is an infectious disease caused by the 
organism Mycobacterium tuberculosis. Despite concerted 
efforts, TB has remained a major global health problem 
[1]. With an estimated 1.8 million TB deaths in 2015, 
including 0.4 million TB-related deaths among human 
immunodeficiency virus (HIV) infected persons, TB is a 
leading infectious killer worldwide [1]. Although improve-
ments have been made in the prevention and treatment 
of HIV, 2.1 million new HIV infections worldwide were 
reported in 2015, resulting in a total of 36.7 million people 
living with HIV globally [2]. The risk of developing TB is 
17- to 22-fold higher for people living with HIV, making 
HIV the most important predisposing factor for TB [3, 
4]. TB and HIV are known to act synergistically on the 
decline of the host immune response, which is fatal if left 
untreated [5, 6].
The treatment of drug-susceptible TB consists of four 
first-line TB drugs (FLD): isoniazid (INH), rifampicin 
(RIF), pyrazinamide (PZA) and ethambutol (EMB) [7]. 
Due to the limited resources in regions with a high TB 
burden, the World Health Organization (WHO) advocates 
standardized treatment with generic, fixed-dose combina-
tion (FDC) formulation tablets for reasons of adherence, 
costs and logistics [7]. The recommended regimen consists 
of a 2-month intensive phase with all four FLDs, and a 
4-month continuation phase with RIF and INH only [7]. 
Despite the utilization of weight-banded dosing, high 
pharmacokinetic (PK) variability has been reported for 
the FLDs in studies investigating the PK of these drugs 
[8–10]. The hollow-fibre infection model and murine 
model conducted with the four FLDs showed that their 
effectiveness is best reflected by the area under the concen-
tration–time curve (AUC)/minimum inhibitory concentra-
tion (MIC) ratio [9, 11–13]. Notably, high PK variability 
and inadequate TB drug exposure are undesirable as high 
drug concentrations could lead to toxicity, while low drug 
exposure predisposes to prolonged treatment, treatment 
failure, relapse, and development of drug resistance [9, 
14–17]. Several factors are known to cause interindividual 
PK variability, including body weight [18], sex [18, 19], 
pharmacogenomics [20, 21] and comorbid conditions such 
as diabetes mellitus [19].
Contrasting findings have been published regarding the 
effect of HIV on TB drug PK variability. Some studies 
showed reduced FLD exposure in HIV-infected patients 
[22–24], while others found no impact of HIV co-infec-
tion [25, 26]. TB drug concentrations are an important 
determinant of clinical response to treatment [27] and 
any potential negative effect of HIV co-infection on the 
PK of TB drugs is therefore crucial. Despite the WHO 
recommendation that all individuals living with HIV 
should be initiated on antiretroviral therapy (ART), result-
ing in high ART coverage of HIV-infected TB patients, 
the effect of HIV infection on the PK of FLDs remains 
relevant. The start of ART does not immediately improve 
the clinical and immunological condition of the patient, 
and the high bacterial burden at the start of TB treatment 
increases the risk of acquired drug resistance if plasma 
drug concentrations are affected by HIV co-infection.
In high endemic TB areas, drug shortages delay ART 
initiation and HIV suppression is not always achieved with 
the available antiretroviral drugs. The aim of this systematic 
review was to investigate the impact of HIV infection on the 
PK of RIF, INH, PZA and EMB.
2  Methods
This systematic review was conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement [28]. The pro-
tocol was registered at PROSPERO (registration number 
CRD42017067250).
A specific clinical question was structured according to 
the population, intervention, comparison, outcome (PICO) 
approach. In this process, ‘P’ represented HIV-positive 
patients with TB co-infection; ‘I’ represented treatment of 
drug-susceptible TB with RIF, INH, PZA and EMB; ‘C’ 
represented HIV-negative TB patients; and ‘O’ represented 
the drug concentration of RIF, INH, PZA and EMB.
To retrieve relevant articles, a systematic electronic data-
base search was performed in MEDLINE (through PubMed) 
and EMBASE on 11 June 2017, and an additional check for 
new published articles was conducted on 29 August 2018. 
The searches were assessed to find original studies evalu-
ating the effect of HIV infection on the PK of RIF, INH, 
PZA and/or EMB. All published studies, without restric-
tion on language and publication date, were eligible. Studies 
in adult and paediatric populations were included. In cases 
where healthy volunteers were included as a control group, 
the study was eligible for inclusion, provided that a group 
of HIV-infected patients without TB was included to assess 
the effect of HIV infection on the PK of the FLDs. Studies 
with HIV-positive patients receiving ART were also eligi-
ble for inclusion, provided that the effect of HIV infection 
on the PK of the FLD was assessed and reported. Studies 
conducted in HIV-positive TB patients without a compara-
tor HIV-negative TB group were included in the systematic 
review but were not eligible for in-depth analysis. Reviews, 
letters, meeting and abstract posters, and correspondence 
were excluded, as were studies without PK data, drug inter-
action studies, and nonhuman studies.
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The search terms used were: (hiv[mesh] OR hiv 
infection[mesh] OR hiv[tiab] OR hiv infection[tiab]) 
AND (tuberculosis[mesh] OR tuberculosis[tiab] OR 
tb[tiab]) AND ((pharmacokinetics[mesh] AND antitu-
bercular agents[mesh]) OR (pharmacokinetics[tiab] 
AND (antitubercular[tiab] OR “TB drugs”[tiab] OR 
antimycobacterial[tiab] OR “antituberculosis drugs”[tiab] 
OR isoniazid[tiab] OR rifampicin[tiab] OR rifampin[tiab] 
OR ethambutol[tiab] OR pyrazinamide[tiab])). The studies 
retrieved from both PubMed and EMBASE were pooled and 
duplicate articles were removed. First, we screened titles and 
abstracts for eligibility, and full-text articles were read by 
the first author (AD) if the abstract was found to be eligible 
or in case of doubt. When the full-text article met all inclu-
sion and exclusion criteria, it was included in the system-
atic review. Primary references of the included studies were 
checked and included if relevant. A second reviewer (LRI) 
conducted the article selection process independently and 
any discrepancies were resolved by discussion. In order to 
identify unpublished studies, the ClinicalTrials.gov website 
(http://clini caltr ials.gov) was searched.
One researcher (AD) first performed data extraction, 
using a pre-discussed structured form, and the second 
researcher (LRI) then independently checked the data extrac-
tion. Variables including age group (paediatric or adult), 
comparator group(s) and the HIV-positive group were noted 
for the included articles. Dose, AUC, peak drug concentra-
tion (Cmax), half-life (t½), time to reach Cmax (Tmax), volume 
of distribution (Vd) and clearance (CL) were extracted from 
the included articles if available and were stratified by group. 
The data were extracted and noted per drug of interest (RIF, 
INH, PZA and EMB). Corresponding authors were con-
tacted by electronic mail for additional data if relevant data 
were missing in the included studies. Finally, the possibility 
of pooling data from included studies was assessed based 
on the risk of bias assessment, PK calculation strategy and 
data presentation.
No validated tool for risk of bias assessment of PK stud-
ies was available. In the absence of such a tool, we assessed 
the risk of bias in a study by noting the presence or absence 
of essential components required for adequate interpreta-
tion of results of a PK study. This provided the opportunity 
to compare the included studies on risk of bias related to 
the methods and design. The following components were 
checked: total sample size, inclusion of both HIV-positive 
and HIV-negative TB groups, proportion of participants with 
 CD4+ < 200 cells/µL or CD4% < 12, proportion of HIV-
positive participants receiving ART, presence of an absorp-
tion test, report of PK-altering morbidities (gastrointestinal, 
hepatic or renal), assessment of interacting comedication, 
calculation of the drug dosage per included group, report of 
directly observed therapy (DOT), number of plasma samples 
drawn per participant, description of specimen handling, use 
of validated analytical methods, method of AUC calculation, 
AUC calculation, stratification of data by HIV infection, and 
the number of participants who were lost to follow-up or 
died during the study period. Studies without a compara-
tor group were only included in the narrative results and 
were excluded from further analysis. The combination of the 
number of plasma samples and the AUC calculation method 
(noncompartmental or model-based) was used to determine 
whether a study had a high or low risk of bias for the AUC 
calculation. Five or more plasma samples per patient, as 
well as utilization of a validated population PK model for 
all FLDs, were considered low risk.
In addition to a narrative synthesis of the results, the 
main results per study and the effect of HIV infection on 
AUC and/or Cmax and additional PK parameters, if available, 
were displayed in a table. The data from patients at different 
months of treatment or at different dosing schemes were pre-
sented separately. When the AUC and/or Cmax for both HIV-
positive and HIV-negative TB groups were available, these 
results were plotted in histograms for each study, comparing 
the AUC and/or Cmax between HIV groups. This provided 
the opportunity to demonstrate an overview of trends. The 
clinical relevance of our findings was assessed in accord-
ance with European Medicines Agency (EMA) guidelines 
[29, 30]. EMA guidelines including bioequivalence cut-off 
values of < 80% and > 125% were also used to estimate the 
clinical relevance of the reported statistically significant 
differences. Studies showing a statistically significant dif-
ference in AUC with an HIV-positive/HIV-negative ratio of 
< 80% or > 125% were considered clinically relevant. Only 
studies reporting data stratified by HIV status were eligible 
for this analysis.
3  Results
In total, 282 articles were retrieved from the searches in Pub-
Med and EMBASE. Systematically assessing the retrieved 
articles resulted in 25 articles being eligible for inclusion. 
One additional article was a report of a preliminary analy-
sis [31] of the study by Antwi et al. [32] and was therefore 
excluded. Two further articles were identified by reviewing 
the references of the first included articles [33, 34], resulting 
in a total of 27 articles being included in the current system-
atic review. No relevant unpublished studies were found on 
the ClinicalTrials.gov website investigating the effect of HIV 
infection on the PK of the FLDs. A flowchart of the selection 
process is presented in Fig. 1.
All included articles were screened for the presence or 
absence of essential components as a means of bias risk 
assessment. Twenty studies were conducted in adults and 
seven studies were conducted in children. Five studies only 
included an HIV-positive TB group, whereas a comparator 
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HIV-negative TB group was lacking [34–38]; therefore these 
studies were excluded for further analysis. Twelve studies 
only included HIV-positive TB participants not receiving 
ART [22–24, 26, 32, 33, 39–44], in ten studies a proportion 
of HIV-positive participants were receiving ART [19, 34, 38, 
45–51], and five studies did not provide information on ART 
use among HIV-positive TB patients [25, 35–37, 52]. In 11 
studies, a limited number of fewer than five blood samples 
were drawn for determination of drug concentrations [19, 25, 
34, 36, 37, 40, 41, 43, 46, 47, 52]. Three studies included 
both an HIV-positive and an HIV-negative TB group but did 
not provide the AUC and Cmax stratified by HIV status [40, 
44, 46]. Two studies only reported Cmax [19, 52], while one 
study determined the percentage of RIF excreted in urine 
[23]. The assessment of risk of bias is presented in Table 1.
Analysis of the extracted data showed that there was clini-
cal, methodological and statistical heterogeneity among the 
included studies. The clinical heterogeneity consisted of 
diversity in outcomes, since outcomes were demonstrated as 
AUC 4, AUC 6, AUC 8, AUC 12, AUC 24 and AUC ∞. The meth-
odological diversity consisted of heterogeneity regarding 
sampling time points, number of samples collected, calcu-
lated AUC range, PK calculation methods and presentation 
of the results. As a result of the clinical and methodological 
heterogeneity, the data also showed high statistical hetero-
geneity as the main outcomes were inconsistent. As a result 
of the diversity, the data were too heterogeneous to allow 
pooling. The PK variability within and between studies was 
high for all four drugs when comparing the mean or median 
AUC and Cmax. The majority of studies presenting PK data 
reported AUC (16 of 27 studies) and Cmax (21 of 27 studies). 
One study reported data on Vd [32], two reported data on CL 
[32, 46], eight reported data on Tmax [22, 26, 32, 33, 36, 37, 
47, 53], and six reported data on t½ [22, 33, 36, 37, 39, 45].
3.1  Rifampicin
In total, 21 of the included articles assessed the effect of HIV 
infection on RIF PK. A narrative synthesis of the results 
is presented in Table 2. Three articles reported a statisti-
cally significantly reduced RIF AUC for the HIV-positive 
TB group compared with the HIV-negative TB group [22, 
32, 49]. One article found that the HIV group had a statis-
tically significantly lower RIF AUC value compared with 
healthy HIV-uninfected volunteers [33], while another study 
found the RIF AUC was statistically significantly higher in 
the HIV-positive TB group than in the HIV-negative TB 
group [26]. Five articles reported a statistically significant 
reduction of Cmax in the HIV-positive TB group compared 
with the HIV-negative TB group [22, 32, 43, 49, 52], and 
one study showed a statistically significantly lower RIF Cmax 
for the HIV group compared with healthy HIV-uninfected 
volunteers [33]. One study demonstrated that excretion of 
RIF was reduced by 27% and 34% in the HIV-positive group 
with diarrhoea and the HIV TB co-infected group without 
diarrhoea, respectively, compared with the HIV-uninfected 
TB group [23]. None of the included articles reported a 
statistically significant difference in Tmax between the HIV-
negative and HIV-positive TB groups. Histograms from 
studies comparing the HIV-negative and HIV-positive TB 
groups are plotted in Figs. 2a and 3a in regard to AUC and 
Cmax, respectively.
3.2  Isoniazid
Twenty included articles assessed the effect of HIV on 
INH PK (Table 2), and none showed statistically signifi-
cant differences in AUC between the HIV-negative and 
HIV-positive TB groups. Two studies, both conducted in 
India, reported a statistically significantly lower Cmax in the 
HIV-positive TB group compared with the HIV-negative TB 
group [22, 49], and one study showed a shorter Tmax for the 
HIV-positive TB group compared with the HIV-negative TB 
group [32]. In the one study that measured excretion of INH, 
a significant reduction of the excretion by 24% was found in 
the HIV-positive group with diarrhoea, and by 23% in the 
HIV-positive TB group without diarrhoea, compared with 
the HIV-uninfected TB group [23]. Histograms from studies 
comparing the HIV-negative and HIV-positive TB groups 
Fig. 1  Study search and selection process
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are plotted in Figs. 2b and 3b in regard to AUC and Cmax, 
respectively.
3.3  Pyrazinamide
Seventeen included articles assessed the effect of HIV on 
PZA PK (Table 2). Two articles found that the HIV-positive 
TB group had statistically significantly reduced AUC com-
pared with the HIV-negative TB group [32, 45]. One article 
reported a statistically significant reduction of Cmax in the 
HIV-positive TB group compared with the HIV-negative 
TB group [52], while another study showed a statistically 
significantly shorter Tmax for the HIV-positive TB group 
compared with the HIV-negative TB group [32]. Histograms 
from studies comparing the HIV-negative and HIV-positive 
TB groups are plotted in Figs. 2c and 3c in regard to AUC 
and Cmax, respectively
3.4  Ethambutol
Twelve included articles assessed the effect of HIV on EMB 
PK (Table 2). Three articles, all conducted in a paediatric 
population, showed that the HIV-positive TB group had sta-
tistically significantly reduced AUC compared with the HIV-
negative TB group [32, 45, 47]. Two of these articles also 
reported a statistically significant reduction of Cmax in the 
HIV-positive TB group compared with the HIV-negative TB 
group [32, 45]. One study showed a statistically significant 
Fig. 2  Histograms of the mean or median area under the concentra-
tion–time curve for the HIV-negative and HIV-positive TB groups per 
study for a rifampicin, b isoniazid, c pyrazinamide and d ethambu-
tol. Asterisk indicates statistical significance; 0–24/0–inf: AUC 24 and 
AUC ∞; 0–8/0–12: AUC 8 and AUC 12; 0–4/0–6; AUC 4 and AUC 6. The 
study by Sahai et al. [33] compared HIV-infected individuals without 
TB with healthy HIV-uninfected volunteers (healthy volunteers). INH 
isoniazid, RIF rifampicin, PZA pyrazinamide, EMB ethambutol, TB 
tuberculosis
 A. Daskapan et al.
increase in Tmax for the HIV-positive TB group compared 
with the HIV-negative TB group [47]. Histograms from 
studies comparing the HIV-negative and HIV-positive TB 
groups are plotted in Figs. 2d and 3d in regard to AUC and 
Cmax, respectively.
3.5  Paediatrics
Seven studies were conducted in paediatric populations 
[32, 38, 42, 45, 47, 49, 51]. One study lacked a compara-
tor TB group [38], but the data were compared with the 
reference ranges reported by Alsultan and Peloquin [54]. 
These researchers concluded that the Cmax of RIF, INH and 
PZA was subtherapeutic in 97%, 28% and 33% of children, 
respectively. Of the remaining six paediatric studies, four 
reported that HIV co-infection in children with TB adversely 
affects the AUC and/or Cmax for at least one of the FLDs 
[32, 45, 47, 49], and two studies did not detect statistically 
significant differences between the groups [42, 51].
3.6  Clinical Relevance
The ratio in AUC between the HIV-positive and HIV-nega-
tive TB groups is shown in Fig. 4. Three of the four studies 
reporting a statistically significantly reduced RIF AUC for 
the HIV-positive TB group compared with the HIV-negative 
TB group were clinically relevantly reduced (≤ 80%) [22, 24, 
49]; the fourth study was not considered clinically relevantly 
Fig. 3  Histograms of the mean or median peak drug concentration 
for the HIV-negative and HIV-positive TB groups per study for a 
rifampicin, b isoniazid, c pyrazinamide and d ethambutol. Asterisk 
indicates statistical significance. The dashed lines represent the gen-
erally cited reference ranges by Peloquin [27]: rifampicin 8–24  µg/
mL; isoniazid 3–6  µg/mL; pyrazinamide 20–50  µg/mL; ethambutol 
2–6  µg/mL. The study by Sahai et  al. [33] compared HIV-infected 
individuals without TB with healthy HIV-uninfected volunteers 
(healthy volunteers). INH isoniazid, RIF rifampicin, PZA pyrazina-
mide, EMB ethambutol, TB tuberculosis
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reduced [32]. The decrease in RIF AUC reported in HIV-
positive patients without TB compared with healthy volun-
teers [33] was considered clinically relevant. The one study 
reporting a statistically significant increase in RIF AUC in 
the HIV-positive TB group compared with the HIV-nega-
tive TB group [26] was also considered clinically relevant 
(≥ 125%). Two studies demonstrated a statistically signifi-
cantly reduced PZA AUC in the HIV-positive TB group 
compared with the HIV-negative TB group. One of these 
studies was considered borderline clinically relevant [45] 
and the other was not considered clinically relevant [32]. The 
results of all four studies showing a statistically significantly 
reduced EMB AUC in the HIV-positive TB group compared 
with the HIV-negative TB group were considered to be clini-
cally relevant [24, 32, 45, 47].
4  Discussion
To our knowledge, this is the first systematic review inves-
tigating the effect of HIV infection on the PK of FLDs. 
We found that the published data were heterogeneous and 
no consistent results emerged from our literature review. 
We also found that for EMB, and in particular for RIF, 
both HIV-positive and HIV-negative TB groups often did 
not achieve the generally accepted threshold (or minimally 
acceptable) Cmax reference range of 8 µg/mL for RIF and 
2 µg/mL for EMB [27]. This phenomenon has already been 
observed in earlier studies, and research is currently being 
conducted investigating higher dosages of RIF [55, 56]. 
Although many studies showed a trend for lower AUC 
and/or Cmax for at least one FLD in the HIV-positive TB 
group compared with the HIV-negative TB group, this did 
not always reach statistical significance. More than half of 
the studies (11 of 20) that included both HIV-positive and 
HIV-negative TB groups showed statistically significantly 
different AUC and/or Cmax for at least one FLD [22, 24, 
26, 32, 33, 43, 45, 47–49, 52]. We focused on AUC and/
or Cmax since most of the studies reported these as primary 
endpoints and they are the most relevant PK predictors of 
clinical outcomes, especially when combined with data on 
MIC [9, 11–13]. The majority of the articles focused on 
the PK of RIF and INH, which is justified by the fact that 
RIF and INH together are the backbone of drug-suscepti-
ble TB treatment.
The effect of HIV infection in TB patients on the PK of 
TB FLDs is an ongoing debate due to lack of consistent 
study results [54]. There may be several reasons to explain 
this inconsistency. First, several studies lacked a comparator 
group, making it difficult to adequately investigate the effect 
of HIV infection on the PK of the FLDs [34–38]. Instead, 
these studies compared with the widely cited reference 
ranges published by Peloquin et al. [27, 57] and Alsultan 
et al. [54, 58]. However, these reference ranges are not age-, 
sex-, and weight-matched and often racial and regional dif-
ferences are not taken into account. Studies have shown that 
female sex is a determinant of higher RIF, INH and PZA 
concentrations and lower EMB concentration [18, 24], and 
older age is a determinant of higher drug levels of all four 
FLDs [24, 58]. Another study reported that RIF exposure 
was significantly lower in people of African descent when 
adjusted for dose and genetic polymorphisms [59]. Although 
comparing PK data with published reference ranges pro-
vides a basic impression, patient characteristics differ highly 
between different populations, and conclusions from studies 
that compare PK findings with published reference ranges 
should therefore be regarded with caution.
Second, we postulate that the effect of HIV infection on 
the PK of the FLDs might often not have been detected due 
to a lack of power. Eleven of the studies that included both 
HIV-positive and HIV-negative TB groups showed statisti-
cally significantly that HIV infection adversely affects the 
PK (mainly AUC and/or Cmax) of at least one of the FLDs 
[22–24, 32, 33, 43–45, 47–49, 52]. Eight studies with both 
groups included did not detect a statistically significant dif-
ference between the two groups for all four FLDs [19, 25, 
39–42, 46, 51], and one study even demonstrated a statisti-
cally significantly higher RIF AUC for the HIV-positive TB 
group [26]. Studies showing statistical differences in drug 
exposures to any of the FLDs had higher sample sizes and 
therefore more power compared with the studies that failed 
to detect such differences.
Fig. 4  Ratio between the AUCs of HIV-positive and HIV-negative 
TB patients for studies showing a statistically significant alteration 
in first-line TB drug AUCs, stratified per drug. The dashed lines rep-
resent the 80–125% (0.8–1.25) cut-off values for clinical relevance; 
all studies with a ratio outside this range were considered clinically 
relevant. RIF rifampicin, PZA pyrazinamide, EMB ethambutol, TB 
tuberculosis, AUC area under the concentration–time curve
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The third potential contributor to the conflicting results 
published might be due to inadequate PK sampling and dif-
ferent PK calculation methods used. Studies unable to detect 
significant differences often had a lower number of collected 
blood samples for determination of drug concentrations. In 
addition to the varying numbers of collected blood samples, 
various different methods for AUC and Cmax estimation were 
used. Some studies determined Cmax by choosing the high-
est concentration among two or three blood draws [19, 25, 
36, 37]. A more reliable method for estimation of Cmax is 
fitting a population PK curve to the measured serum con-
centration–time data using Bayesian estimation [60]. Due to 
the varying number of blood samples drawn over a certain 
period of time, and the different methods used (model-based 
or noncompartmental) for the estimation of the AUC, the 
curves used to estimate AUCs in the included studies var-
ied from 0 to 4 h [47] to 0 to 24 h [48, 50], thereby leading 
to potential loss of information. Collecting multiple blood 
samples over a longer period of time ensures the absorp-
tion, distribution, metabolism and elimination phases are 
adequately captured post-dose, which results in more accu-
rate estimations of the AUC. Another approach is limited 
sampling strategies (LSS) or computational posteriori esti-
mations using Bayesian methods [60–62]. In this systematic 
review, we therefore used the combination of the number 
of blood samples drawn, the use of PK modelling, and the 
implementation of validated bioanalytical methods for the 
assessment of risk of bias.
Another explanation for the contrasting results in the 
included studies is variation in the clinical severity of HIV 
infection, the degree of immunosuppression, and the use of 
ART. Several studies have demonstrated that the PK of the 
FLDs is more adversely altered in cases of more advanced 
stages of HIV [22, 33, 52]. In the studies that did not find 
lower drug exposures among HIV-positive TB patients 
compared with the HIV-negative TB group, the majority of 
co-infected patients had higher  CD4+ cell counts and were 
receiving ART [41, 45, 48, 50], or data on HIV progression 
were lacking [24, 42]. It is conceivable that successful ART 
mitigates the effect of HIV infection on TB drug PK parame-
ters. In 10 studies, a proportion of the included HIV-positive 
participants was receiving ART [19, 34, 38, 45–51], while 
five studies did not provide information on ART use among 
HIV-positive TB patients [25, 35–37, 52]. The simultaneous 
use of FLD and ART can result in drug–drug interactions 
[63, 64] and can potentially lead to nonadherence.
Among the included studies, a high interindividual PK 
variability was found that was not merely attributable to 
HIV infection. We found that in the majority of studies, 
both HIV-positive and HIV-negative TB patients had an RIF 
Cmax below the minimum reference range; the same applied 
for a proportion of the studies reporting EMB Cmax. This 
high variability involves the interplay of multiple factors, 
ranging from drug compounding to the distribution of the 
drug molecules at the site of infection. Drug formulation 
[24], pharmacogenomics [20, 21], racial and ethnic differ-
ences [20, 59], sex [19, 24], body weight [18], advanced 
immunosuppression [22, 33], comorbid conditions such as 
diabetes mellitus [19, 23], comedication [63, 64] and nutri-
tional status [43, 65] are the most investigated and salient 
factors. It is worth mentioning that a statistically significant 
reduction of FLD exposure in the HIV-positive TB groups 
does not necessarily have to be clinically relevant and that 
this should be explored in future studies that include treat-
ment outcomes. In the absence of such studies at present, the 
cut-off values of the EMA guidelines (< 80% and > 125%) 
[29, 30] offer an alternative way to determine the clinical 
relevance of decreased or increased FLD exposures. Since 
these cut-off values are based on drug exposure, only studies 
reporting a statistically significant change in AUC could be 
included in the assessment. With the exception of the stud-
ies by Antwi et al. [32] and Taylor and Smith [26] in regard 
to RIF, and Antwi et al. [32] in regard to PZA AUC, all 
studies reporting a statistically significant alteration in FLD 
AUC were considered clinically relevantly reduced [22, 24, 
26, 32, 33, 45, 47, 49]. Taking the risk of bias assessment 
(Table 1) into account in relation to the studies included in 
the systematic review, we postulate that in patients prone to 
low FLD exposure, HIV infection might even further reduce 
drug exposure [66], leading to poor treatment outcome [9]. 
While not a substitute for clinical judgement, therapeutic 
drug monitoring (TDM) could be a powerful tool for iden-
tifying patients with subtherapeutic FLD levels at risk of 
poor treatment outcomes [62, 67, 68]. TDM performed early 
during TB treatment in patients at risk of subtherapeutic 
FLD levels may improve treatment response and may also 
prevent toxicity [68, 69]. For resource-limited settings, dried 
blood spot analysis combined with LSS or drug concentra-
tion measurements in saliva with thin-layer chromatography 
might provide a solution to address the problems of patients 
with a burden of blood draws, as well as costs [61, 70, 71].
A recent study by Hiruy et al. reported that HIV-negative 
children with TB are at risk of subtherapeutic concentrations 
for all FLDs [72]. Younger age has a considerable impact 
on TB drug exposure and should be considered in dosing 
recommendations. This has been attributed to children hav-
ing a larger liver size and higher hepatic metabolic activity 
in proportion to body weight [53]. Our findings suggest that 
RIF and EMB exposures appear to be adversely affected in 
paediatric HIV-positive TB populations, even after admin-
istration of the revised WHO-recommended weight-based 
dosages. The clinical relevance of such reduced FLD expo-
sures has to be urgently further investigated in paediatric 
populations.
A broad and comprehensive literature search was con-
ducted systematically that allowed the identification of 
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studies that included data on the effect of HIV infection on 
the PK of the FLDs. A strength of this systematic review is 
that it provides a good overview of the available literature 
and exposes current knowledge gaps. However, the sys-
tematic review also has some limitations. Despite the high 
disease burden, relatively few data were available and with 
variable quality, increasing the risk of bias. Furthermore, 
we chose to include all articles that included data on the 
effect of HIV infection on the PK of the FLDs, to prevent 
loss of information; therefore, studies lacking a comparator 
group and with participants receiving ART were included, 
potentially introducing bias. A more in-depth analysis was 
restricted to studies that had both an HIV-positive and HIV-
negative TB group. Although no registered and unpublished 
studies were found in the database search, publication bias 
cannot be completely excluded. A recent study demonstrated 
that higher MIC values were associated with a greater risk 
of relapse than lower MIC values [73]. None of the studies 
included in this systematic review reported data on MIC. 
Lastly, the published data were too heterogeneous and were 
reported highly inconsistently, to allow pooling of the data. 
Due to methodological and statistical heterogeneity, sub-
group analyses were also not appropriate.
5  Conclusion
Relatively few studies have been published investigating the 
effect of HIV infection on the PK of the FLDs. The available 
studies provide a heterogeneous dataset from which consist-
ent results could not be obtained. Therefore, we could make 
no general recommendation with respect to dosing. There is 
a need for a consistent and homogeneous approach to studies 
and for a uniform quality assessment tool specifically for PK 
studies. Taking clinical relevance into account, we postulate 
that HIV infection may exacerbate a susceptibility to low 
FLD exposures, with potential detrimental consequences 
for treatment outcomes. This systematic review may inform 
further studies investigating the effect of HIV infection on 
the PK of the FLDs. A population PK analysis may provide a 
solution for the inability of pooling of the currently available 
data, as a population PK analysis can adjust for confounders. 
In addition, a prospective study with both an HIV-positive 
and HIV-negative TB group, including data on pharmacody-
namics and treatment outcome, is needed to provide further 
insight into the highly complex PK of the FLDs.
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